IR – Press Release 2017-05-15: Zynex Announces 2017 First Quarter Results

May 15, 2017

Zynex Announces 2017 First Quarter Results

LONE TREE, Colo., May 15, 2017 /PRNEWSWIRE/ — Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announces 2017 first quarter financial results.LONE TREE, Colo., May 15, 2017 /PRNewswire/ — Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announces 2017 first quarter financial results.

President and CEO Commentary:

Thomas Sandgaard, CEO commented: “The first quarter of 2017 was a continuation of a strong second half of 2016 with net income of $478,000 and revenue of $3.4 million for the quarter. Our gross profit margins are still strong at 76% and a focus on lowering fixed expenses is paying off in terms of positive cash flow and a strong, positive net income.

“We received financing of $1 million towards the end of the first quarter which has been extremely helpful in terms of building enough products to keep up with sales orders and now providing our sales force with demonstration units. We are also experiencing a significant improvement in cash collections as a result of improved billing efforts and are streamlining our infrastructure to accommodate further growth in orders. Sales order growth had been limited the past couple of quarters due to cash constraints and not having any availability to borrow under our line of credit. We continue to reduce the balance on our line of credit and the balance at the end of April 2017 was $1.9 million, down from $2.7 million at the beginning of the year.

“We currently estimate our second quarter revenue to come in at approximately $3.8 million, a net income of $500,000 and EBITDA around $650,000. EBITDA in the first quarter of 2017 was $580,000 and for the full year 2016 it was $640,000.

“Our long term goals continue to be taking advantage of the huge void in the electrotherapy industry realizing annual revenue in excess of $250 million, a listing of a national stock exchange and also launching our Blood Volume Monitor into the hospital market for non-invasively detecting blood loss and internal bleeding.”

Summary of Financial Results:

The Company’s net revenue was flat compared to the year before, $3,436,000 for the first quarter of 2017, compared to $3,477,000 for the first quarter in 2016. The lack of growth was primarily impeded by the lack of cash and available borrowings under the line of credit to facilitate the production of units to fill orders timely. Cost of Goods Sold decreased from $983,000 in the first quarter of 2016 compared to $809,000 in the same quarter in 2017 which reflects an increase in Gross Profit Margin to 76% versus 72% in the same period 2016.

The Company reported Selling, General and Administrative (“SG&A”) expenses of $2,047,000 for first quarter 2017, compared to $2,844,000 for the first quarter 2016. The Company’s SG&A expenses decreased 28% compared to the same period last year, continuing a trend of decreasing operating expenses, primarily reduced employee expenses, resulting in an improvement of the quarter’s operating result by $930,000.

The Company reported net income of $478,000 or one cent per share for the first quarter of 2017 compared to a net loss of $440,000 in the first quarter of 2016 or one cent per share.

The Company’s cash and line of credit balance as of March 31, 2017 was $462,000 and $2,171,000, respectively, as compared to cash and line of credit balance as of December 31, 2016 of $247,000 and $2,771,000.

Webcast Details: Monday, May 15, 2017 at 9:00 a.m. MT – 11:00 a.m. ET

To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:

Canada Toll Free:




    March 31,     December 31,  
    2017     2016  
Current Assets:                
Cash   $ 462     $ 247  
Accounts receivable, net     2,956       3,028  
Inventory, net     203       107  
Prepaid expenses     148       40  
Total current assets     3,769       3,422  
Property and equipment, net     571       580  
Deposits     55       55  
Intangible assets, net     28       34  
Total assets   $ 4,423     $ 4,091  
Current Liabilities:                
Line of credit   $ 2,171     $ 2,771  
Unsecured subordinated promissory notes     690        
Debt issuance costs     (442 )      
Current portion of capital leases     135       118  
Accounts payable     2,521       2,879  
Deferred revenue     54       54  
Income taxes payable     103       94  
Accrued payroll and payroll taxes     642       732  
Deferred insurance reimbursement     880       880  
Accrued expenses     199       217  
Total current liabilities     6,953       7,745  
Debt issuance costs, less current portion     160       136  
Capitalized leases, less current portion     88        
Warranty liability     12       12  
Total liabilities     7,213       7,893  
Stockholders’ Deficit:                
Common stock, $.001 par value, 100,000,000 shares authorized, 32,048,484 (2017) and 31,271,234 (2016) shares issued and outstanding     32       31  
Paid-in capital     6,564       6,032  
Accumulated deficit     (9,297 )     (9,776 )
Total Zynex, Inc. stockholders’ deficit     (2,701 )     (3,713 )
Non-controlling interest     (89 )     (89 )
Total stockholders’ deficit     (2,790 )     (3,802 )
Total liabilities and stockholders’ deficit   $ 4,423     $ 4,091  






    Three months ended March 31,  
    2017     2016  
Net revenue:                
Product sales   $ 1,862     $ 2,583  
Product supplies     1,574       894  
      3,436       3,477  
Operating expenses:                
Cost of revenue – rental, product & supply     809       983  
Selling, general and administrative expense     2,047       2,844  
Income (loss) from operations     580       (350 )
Other income (expense):                
Interest expense     (93 )     (94 )
Total other income (expense)     (93 )     (94 )
Income (loss) before income taxes     487       (444 )
Income taxes     (9 )      
Net income (loss)   $ 478     $ (444 )
Net income (loss) per share :                
Basic   $ 0.01     $ (0.01 )
Diluted   $ 0.01     $ (0.01 )
Weighted average number of common shares outstanding:                
Basic     32,048,484       31,271,234  
Diluted     32,824,734       31,271,234  






    Three months ended March 31,  
    2017     2016  
Cash flows from operating activities:                
Net cash provided by operating activities   $ 435     $ 666  
Cash flows from investing activities:                
Change in inventory used for rental     1       10  
Net cash  provided by investing activities     1       10  
Cash flows from financing activities:                
Net borrowing (repayments) on line of credit     (600 )     (640 )
Payments on capital leases and other obligations     379       (20 )
Net cash (used in) provided by financing activities     (221 )     (660 )
Net increase (decrease) in cash     215       16  
Cash at the beginning of the period     247       8  
Cash at the end of the period   $ 462     $ 24  
Supplemental cash flow information:                
Interest paid   $ 93     $ 94  

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company’s proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit:

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2016.

Zynex, Inc.
(303) 703-4906


To view the original version on PR Newswire, visit:

Copyright (C) 2016 PR Newswire. All rights reserved